Trends in Pharmacological Sciences

Article	Citations
Subscription and Copyright Information	644
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease	424
Subscription and Copyright Information	252
Subscription and Copyright Information	178
Subscription and Copyright Information	163
Advisory Board and Contents	157
Structural asymmetry in FGF23 signaling	153
Subscription and Copyright Information	142
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1	140
Targeting of Potassium Channels in Cardiac Arrhythmias	131
Assembling the P450 puzzle: on the sources of nonadditivity in drug metabolism	131
Structural pharmacology and mechanisms of GLP-1R signaling	120
Muscarinic receptors: from clinic to bench to clinic	106
Shearing of surface mucin saps tumor cell strength	104
Advancing chemical carcinogenicity prediction modeling: opportunities and challenges	104
Direct in vivo CAR T cell engineering	92
Peptides as a therapeutic strategy against Klebsiella pneumoniae	90
Targeting complement in neurodegeneration: challenges, risks, and strategies	88
Compstatins: the dawn of clinical C3-targeted complement inhibition	88
Therapeutic inhibition of ferroptosis in neurodegenerative disease	80
Advisory Board and Contents	79
Advisory Board and Contents	78
Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy	78
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors	77
Phenotypic approaches for CNS drugs	71

Emerging strategies for beta cell transplantation to treat diabetes	68
A smart hospital-driven approach to precision pharmacovigilance	65
Ribosome-directed cancer therapies: the tip of the iceberg?	62
HSV-1 as a gene delivery platform for cancer gene therapy	61
Advisory Board and Contents	60
Liquid–liquid phase separation: a principal organizer of the cell’s biochemical activity architecture	60
A deep dive into degrader-induced protein-protein interfaces	59
A perspective on psychedelic teratogenicity: the utility of zebrafish models	57
Genetically engineered loaded extracellular vesicles for drug delivery	56
Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease	56
Engineering ACE2 decoy receptors to combat viral escapability	56
Advisory Board and Contents	56
siRNA drug Leqvio (inclisiran) to lower cholesterol	56
Leveraging human microbiomes for disease prediction and treatment	56
Mentoring future science leaders to thrive	54
Could dexmedetomidine be repurposed as a glymphatic enhancer?	52
Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19	51
Close to a year in TIPS’ saddle – I am optimistic	50
The structure, function, and pharmacology of MRGPRs	50
Subscription and Copyright Information	50
Emerging approaches to induce immune tolerance to therapeutic proteins	49
Thriving as members of under-represented groups in pharmacology-related careers	49
Lipoxygenases in chronic liver diseases: current insights and future perspectives	48
Suzetrigine for moderate to severe acute pain	47
Alzheimer’s therapeutic development: shifting neurodegeneration to neuroregeneration	47
GPR35, ally of the anti-ischemic ATPIF1-ATP synthase interaction	47
Advancing non-destructive analysis of 3D printed medicines	46
Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD	45
The road less traveled: activating an oncogenic kinase	44
The promise of targeted protein degradation approaches	44
Advisory Board and Contents	44
Building unconventional G protein-coupled receptors, one block at a time	43
Salt-inducible kinases: new players in pulmonary arterial hypertension?	43
Fragment-based drug design facilitates selective kinase inhibitor discovery	42
Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease	42
Targeting the TGF-β signaling pathway for resolution of pulmonary arterial hypertension	41
Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients	41
Inhalable neutralizing antibodies – promising approach to combating respiratory viral infections	40
Promising neuroimmune targets and drugs for CNS diseases	39
A novel function of the M2 muscarinic receptor	39
Subscription and Copyright Information	39
Advisory Board and Contents	39
The end of the beginning in understanding SLC22 polyspecificity	38
Nanocarriers for oral delivery of biologics: small carriers for big payloads	37
Validation of agent-based models of surface receptor oligomerisation	37
BTK inhibitors: past, present, and future	34
Frizzleds act as dynamic pharmacological entities	34
Advisory Board and Contents	33
Decoding pseudouridine: an emerging target for therapeutic development	33
Monkeypox: potential vaccine development strategies	33

Eflornithine for treatment of high-risk neuroblastoma	33
Targeting intracellular protein–protein interactions with macrocyclic peptides	33
Recent advances in generative biology for biotherapeutic discovery	32
Voltage-gated ion channels in epilepsies: circuit dysfunctions and treatments	31
SEAKER cells coordinate cellular immunotherapy with localized chemotherapy	31
Demographic diversity in platelet function and response to antiplatelet therapy	31
Metabolic regulation in normal and leukemic stem cells	31
Engineered antibody fusion proteins for targeted disease therapy	31
Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches	29
GPR35: from enigma to therapeutic target	29
Neurofilament light chain as a biomarker of chemotherapy-induced peripheral neuropathy	28
Circulating tumor cells in precision medicine: challenges and opportunities	28
Histone lysine acetyltransferase inhibitors: an emerging class of drugs for cancer therapy	27
Development of PROTACs using computational approaches	27
Subscription and Copyright Information	27
Subscription and Copyright Information	26
Subscription and Copyright Information	25
Magnesium for disease treatment and prevention: emerging mechanisms and opportunities	25
Biochemical perspectives on targeting KMT2 methyltransferases in cancer	24
Intra- and intercellular signaling pathways associated with drug-induced cardiac pathophysiology	24
A novel anticancer pharmacological agent targeting mitochondrial complex I	24
Harnessing associative learning paradigms to optimize drug treatment	24
Tackling chronic kidney disease in diabetic patients with finerenone	24
Subscription and Copyright Information	24
Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis	24
Commemorating insulin's centennial: engineering insulin pharmacology towards physiology	23
Boosting CAR-T cell therapy through vaccine synergy	23
Visceral obesity and HFpEF: targets and therapeutic opportunities	23
Targeting sensory neuron GPCRs for peripheral neuropathic pain	23
Modulation of Wnt–β-catenin signaling with antibodies: therapeutic opportunities and challenges	23
Biologics and cardiac disease: challenges and opportunities	23
High-power screening (HPS) empowered by DNA-encoded libraries	22
Taming PRMT5–adaptor protein interactions	22
Neutrophil extracellular traps in wound healing	22
Teaching an old dog new tricks: repurposing β-lactams	22
Subscription and Copyright Information	22
Recent advancements in vaccine research and development	22
Crosstalk between androgen receptor and protein kinase G signaling in bone: implications for osteoporosis therapy	22
Targeting methionine aminopeptidase 2 in cancer, obesity, and autoimmunity	21
Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics	21
Potential for targeting small heat shock protein modifications	21
Circadian biology to advance therapeutics for mood disorders	21
NLRP3 and pyroptosis blockers for treating inflammatory diseases	21
GABAA receptors as targets for treating affective and cognitive symptoms of depression	21
Challenges and opportunities associated with rare-variant pharmacogenomics	21
Partial agonists go molecular	21
The structure and function of YTHDF epitranscriptomic m6A readers	20
Advisory Board and Contents	20
Harnessing UBR5 for targeted protein degradation of key transcriptional regulators	20
Targeted protein degrader development for cancer: advances, challenges, and opportunities	19
Glymphatic-stagnated edema induced by traumatic brain injury	19
GPCR-dependent and -independent arrestin signaling	19
Odorant receptors as potential drug targets	18
Membrane protein production and formulation for drug discovery	18
The Importance of Apparent pKa in the Development of Nanoparticles Encapsulating siRNA and mRNA	18
Microfluidic technologies for drug discovery and development: friend or foe?	18
Bridging the gap in neuropsychiatric translational research	17
Advisory Board and Contents	17
Malolactone strikes: K-Ras-G12D's Achilles' heel	17
Advisory Board and Contents	17
Learning from natural design for local anesthetic delivery	17
Hans Jürg Schatzmann (1924–2021)	17
Advancing small-molecule drug discovery by encoded dual-display technologies	16
Leveraging VGLUT3 Functions to Untangle Brain Dysfunctions	16
Electroceuticals: emerging applications beyond the nervous system and excitable tissues	16
KRASG12C/mTORC1 inhibition: a powerful duo in NSCLC therapeutics	16
NET-targeted therapy: effects, limitations, and potential strategies to enhance treatment efficacy	15
Celiac disease: mechanisms and emerging therapeutics	15
Subscription and Copyright Information	15
Emerging epigenetic insights into aging mechanisms and interventions	15
Harnessing deep learning for enhanced ligand docking	14
Leveraging non-enzymatic functions of LSD1 for novel therapeutics	14
Advisory Board and Contents	14
Advisory Board and Contents	14
Glaucoma: neuroprotection with NAD-based therapeutic interventions	14
Mitochondrial dynamics proteins as emerging drug targets	14
Apart, together: reflections on the COVID-19 pandemic	14
Structural perspective of class B1 GPCR signaling	14
Screening strategies for identifying RNA- and ribonucleoprotein-targeted compounds	14
Thapsigargin: key to new host-directed coronavirus antivirals?	14

Advisory Board and Contents	14
Advisory Board and Contents	13
Safety of medicines and vaccines – building next generation capability	13
Multiple hERG channel blocking pathways: implications for macromolecules	13
Advisory Board and Contents	13
Current landscape of preclinical models of diabetic cardiomyopathy	13
Subscription and Copyright Information	13
Subscription and Copyright Information	13
Subtyping for pancreatic cancer precision therapy	13
Pharmacological targeting of the tumor–immune symbiosis in glioblastoma	13
Advisory Board and Contents	13
Isoform-selective targeting of PI3K: time to consider new opportunities?	13
Reactive chemistry for covalent probe and therapeutic development	13
Human skin-on-a-chip for mpox pathogenesis studies and preclinical drug evaluation	13
Endometriosis: cannabidiol therapy for symptom relief	13
Advances in spatial mass spectrometry enable in-depth neuropharmacodynamics	13
A mechanism for ligand-dependent activation of AHR	12
Engineering extracellular vesicles for diagnosis and therapy	12
TNIK’s emerging role in cancer, metabolism, and age-related diseases	12
Present and future of microglial pharmacology	12
Nanodelivery of cGAS-STING activators for tumor immunotherapy	11
Advisory Board and Contents	11
Casimersen for the treatment of Duchenne muscular dystrophy	11
Subscription and Copyright Information	11
Targeting galectin-3 in inflammatory and fibrotic diseases	11
Recent breakthroughs and future directions in drugging aquaporins	11
Advisory Board and Contents	11
Targeting chromosomal instability and aneuploidy in cancer	11
Targeting sialylation to treat central nervous system diseases	11
Subscription and Copyright Information	11
IRAK4: potential therapeutic target for airway disease exacerbations	11
Channeling Force in the Brain: Mechanosensitive Ion Channels Choreograph Mechanics and Malignancies	10
Advisory Board and Contents	10
Paving the way for designing drugs targeting TMEM16A	10
Calcitonin/PAC1 receptor splice variants: a blind spot in migraine research	10
In vivo functions of p75NTR: challenges and opportunities for an emerging therapeutic target	10
Unifying mechanism behind the onset of acquired epilepsy	10
Subscription and Copyright Information	10
Subscription and Copyright Information	9
Mutations in muscle-type creatine kinase impact HIV prevention	9
Giving ERK a jERK from the endosome	9
Pharmacological targets at the lysosomal autophagy–NLRP3 inflammasome crossroads	9
Emerging paradigms and recent progress in targeting ErbB in cancers	9
Fezolinetant for menopausal hot flashes and night sweats	9
Targeting in silico GPCR conformations with ultra-large library screening for hit discovery	9
Structural snapshot of a β-arrestin-biased receptor	9
Iron metabolism: pathophysiology and pharmacology	9
Current views on N-glycolylneuraminic acid in therapeutic recombinant proteins	9
Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities	9
Therapeutic targeting of exportin-1 beyond nuclear export	9
Efflux Limits Tumor Drug Delivery Despite Disrupted BBB	9
Repurposing trifluoperazine for glioblastoma treatment	9
Copper homeostasis and cuproptosis in cardiovascular disease therapeutics	9
Heterobifunctional small molecules to modulate RNA function	9
Subscription and Copyright Information	8
A quick guide to networking for scientists	8
Targeting neurological abnormalities in lysosomal storage diseases	8
Guanylate cyclase-C agonists as peripherally acting treatments of chronic visceral pain	8
VMAT structures reveal exciting targets for drug development	8
Targeting TRPM channels for cerebral ischemia–reperfusion injury	8
The Prognosis of Arthrofibroses: Prevalence, Clinical Shortcomings, and Future Prospects	8
Cholesterol – the devil you know; ceramide – the devil you don’t	8
The potential of long noncoding RNA therapies	8
PPAR agonists for the treatment of neuroinflammatory diseases	7
Regulation of drug-metabolizing enzymes by sex-related hormones: clinical implications for transgender medicine	7
Small Molecule Drug Discovery for Neglected Tropical Snakebite	7
Subscription and Copyright Information	7
Subscription and Copyright Information	7
The structure and function of olfactory receptors	7
Targeting the mitochondrial chaperone TRAP1: strategies and therapeutic perspectives	7
Differences in pathogenicity among the mpox virus clades: impact on drug discovery and vaccine development	7
Implications of innate immune sexual dimorphism for MASLD pathogenesis and treatment	6
ACK1/TNK2 kinase: molecular mechanisms and emerging cancer therapeutics	6
Hypothalamic AMPK as a possible target for energy balance-related diseases	6
Therapeutic Targeting of IL-11 for Chronic Lung Disease	6
Advances in cell therapy: progress and challenges in hematological and solid tumors	6
Targeting Fks1 proteins for novel antifungal drug discovery	6
Emerging mechanisms and therapeutics in inflammatory muscle diseases	6
Some assembly required: a single-RNA vaccine against enterovirus-D68	6
Data and AI-driven synthetic binding protein discovery	6
Subscription and Copyright Information	6
Subscription and Copyright Information	5
How can quantum computing be applied in clinical trial design and optimization?	5
Protein–protein interactions: developing small-molecule inhibitors/stabilizers through covalent strategies	5
Electrophilic Natural Products as Drug Discovery Tools	5
Mitochondrial quality control mechanisms as therapeutic targets in doxorubicin-induced cardiotoxicity	5
Glycine: a long-sought novel ligand for GPR158	5
Targeting solute carriers to modulate receptor–ligand interactions	5
Advisory Board and Contents	5
Targeting mitochondrial dynamics and redox regulation in cardiovascular diseases	5
Mitochondrial quality control: prime targets for antiviral therapy?	5
Pharmacogenomics in treatment of depression and psychosis: an update	5
FOXO transcription factors as therapeutic targets in human diseases	5
The future of neuroimmunology research for CNS disease therapeutics	5
Ganaxolone for management of seizures associated with CDKL5 deficiency disorder	5